Analyst picks & changes

Centocor Inc.


Business: Biopharmaceuticals

Morgan Stanley analyst Eric Hecht maintained his "buy" on the Malvern, Penn., company's shares following second quarter results below the Street consensus estimate of a loss of 13 cents.

Read the full 348 word article

How to gain access

Continue reading with a
two-week free trial.